| Autor: |
Recondo, Gonzalo, Recondo, Gonzalo, Galanternik, Fernando, Greco, Martín, de la Vega, Máximo, Diaz Cantón, E., E. Valsecchi, Matías |
| Zdroj: |
Reviews on Recent Clinical Trials; June 2016, Vol. 11 Issue: 2 p87-92, 6p |
| Abstrakt: |
Lung cancer is a major public health problem worldwide and the leading cause of cancerrelated mortality in developed countries. Significant advances have been made especially with the discovery of targeted agents. However, only a small proportion of patients carry activating mutations; until recently conventional chemotherapy and angiogenesis inhibitors were the preferred treatment for the vast majority of patients. Now, the successful experience of anti-PD-1 agents may have opened the door to a novel and previously unexplored dimension in the treatment of lung cancer: immunotherapy. In this mini-review we will discuss the current applications and future consequences related this topic, paying special attention to the clinical studies that constitute the scientific evidence to supports its use. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
